![[Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta.](/media/k2/items/cache/2f7c13232e13404e23cfd28dd9d8bff9_L.jpg)
[Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta.
Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest – Clover Biopharmaceutical Commentary: New Chinese vaccine could bolster global arsenal – Science
The post [Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Non-inferiority RCT: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended VTE Treatment
- Systematic Review: Shorter Antibiotic Courses Often Prove Non-Inferior for Common Bacterial Infections
- Network Meta-analysis: Oseltamivir Fails to Improve Key Outcomes in Nonsevere Influenza
- Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies
- Introducing Our Free WhatsApp Channels for Daily Internal Medicine Articles!